Reuters logo
BRIEF-Orexigen Therapeutics - pursuing potential actions including merger or sale of co
October 16, 2017 / 10:31 AM / 2 months ago

BRIEF-Orexigen Therapeutics - pursuing potential actions including merger or sale of co

Oct 16 (Reuters) - Orexigen Therapeutics Inc

* Orexigen Therapeutics Inc says ‍expects total revenues for Q3 of 2017 to be between about $18.1 million and $19.1 million-SEC filing​

* Orexigen Therapeutics-‍management evaluating whether there are relevant conditions to raise substantial doubt about co’s ability to continue as going concern​

* Orexigen Therapeutics-in connection with evaluation, ‍co currently pursuing number of potential actions, including attempting to pursue merger or sale of co Source text: (bit.ly/2yrhbmK) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below